M., Gaude, E., Turrell, F
Salas-Whalens clinical stance is clear: these drugs should be considered first-line therapy for the disease of obesity, not a last resort after years of failed diets
Two-way ANOVA main effects are reported and Bonferroni post hoc multiple-comparison analyses applied when relevant for interpretation
In this long form guide we explain the science, what clinical experience shows, and what you can try today to diagnose and solve the problem while protecting your health goals
Malhou 15 septembre 2021 Bonjour
According to NICE guidelines (NG28), GLP-1 receptor agonists may be considered for type 2 diabetes when metformin and other treatments have not achieved glycaemic targets